Olmesartan to Losartan Dose Equivalents in Heart Failure with Renal Impairment

Preferred ARB Alternatives to Olmesartan

The American College of Cardiology recommends candesartan and valsartan as superior alternatives to losartan for heart failure patients with impaired renal function, based on mortality and hospitalization data, with a dose of candesartan 4-32 mg once daily and valsartan 80-320 mg daily, divided into twice daily dosing 1, 2
Candesartan and valsartan have the strongest evidence for reducing hospitalizations and mortality in heart failure patients intolerant to ACE inhibitors, making them the preferred alternatives over losartan in this clinical context 1, 2

The dose equivalency for olmesartan to losartan is 20 mg daily of olmesartan to 50 mg daily of losartan, and 40 mg daily of olmesartan to 100 mg daily of losartan, as recommended by the American College of Cardiology 1, 2

The American College of Cardiology recommends checking blood pressure, serum creatinine, and potassium within 1-2 weeks after initiating any ARB, with more frequent surveillance required for patients with systolic BP <80 mmHg, low sodium, diabetes, or pre-existing renal dysfunction 1, 2
Patients with serum potassium >5.0 mmol/L or creatinine >250 μmol/L should not initiate ARB therapy until these conditions are corrected, as recommended by the European Heart Journal 3

The American College of Cardiology advises against combining ARBs with both ACE inhibitors and aldosterone antagonists, as this dramatically increases risks of renal dysfunction and hyperkalemia without mortality benefit 1, 2
The American College of Cardiology also recommends avoiding the addition of ARBs to adequate-dose ACE inhibitors, as there is no evidence of added benefit and increased risk of adverse effects 1

The American College of Cardiology recommends olmesartan 20-40 mg once daily, telmisartan 40-80 mg once daily, and losartan 50-100 mg once daily for hypertension treatment 4, 5
The American Heart Association suggests that all three medications can be administered with or without food, but dosing should be individualized based on patient response 5

The European Society of Cardiology recommends ARBs for patients who do not tolerate ACE inhibitors for symptomatic treatment of heart failure, with a strength of evidence level of I 6, 7
ARBs like candesartan and valsartan have demonstrated benefit in reducing hospitalizations and mortality in heart failure patients intolerant to ACE inhibitors, with a moderate to high strength of evidence 7

The European Heart Journal notes that all three ARBs have similar side effect profiles, with fewer adverse effects compared to ACE inhibitors, and recommends monitoring blood pressure, renal function, and potassium levels 5, 6
Patients with systolic blood pressure below 80 mm Hg, low serum sodium, diabetes mellitus, and impaired renal function require closer monitoring during therapy with any ARB, according to the American Heart Association 5